Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610849 | 0.86 | KEAP1 (0.68) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL27483674 | 0.86 | KEAP1 (0.68) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL4741114 | 0.86 | KEAP1 (0.68) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL1234889 | 0.84 | KEAP1 (0.70) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL2062807 | 0.84 | KEAP1 (0.70) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL522945 | 0.84 | KEAP1 (0.70) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL13266147 | 0.83 | POLB (0.76) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL14753782 | 0.83 | CYP3A4 (0.70) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL14753777 | 0.83 | CYP3A4 (0.70) | KEAP1NFE2L2POLBALDH1A1CHRM2 | |
| SCHEMBL4618170 | 0.82 | KEAP1 (0.72) | KEAP1NFE2L2POLBALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | disclosed |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNIV CASE WESTERN RESERVE (US) | 2017-03-16 | — | — | US | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-8324282-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066464-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, NTPCR, GUSB | KEAP1 1633/4885NFE2L2 1603/4885POLB 225/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | KEAP1 3297/4885NFE2L2 1442/4885POLB 32/4885 |
| US-20180185403-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | UNG, TP53, OGG1 | KEAP1 1632/4885NFE2L2 1237/4885POLB 34/4885 |
| US-20170071965-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | KEAP1 1642/4885NFE2L2 698/4885POLB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.